The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Conrady, Christopher D.; Hartnett, M. Elizabeth

doi:10.17925/usor.2017.10.01.57

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 92 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study showed fewer re‐treatments in the bevacizumab group, but this was isolated to infants with ROP in zone 1 5. These agents inhibit VEGF which is an important growth factor in angiogenesis 6…”

mentioning

confidence: 83%

Ranibizumab—The jury is still out

Allen

Keir

2020

Acta Paediatrica

View full text Add to dashboard Cite

mentioning

confidence: 83%

Ranibizumab—The jury is still out

Allen

Keir

2020

Acta Paediatrica

View full text Add to dashboard Cite

“…Dysregulation of VEGF is considered one of the underlying mechanisms for ROP [14]. Injection of anti-VEGF agents like Ranibizumab, Bevacizumab, and Aflibercept into the vitreous is a popular strategy for management of diseases associated with vaso-proliferation and hyperpermeability in adult ophthalmologic practices [3].…”

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of Intravitreal Ranibizumab versus Laser Therapy for Retinopathy of Prematurity

Elabbasy,

Abdelbaky,

Al-Shehri

et al. 2022

Arch. Pharm. Pract

View full text Add to dashboard Cite

The therapeutic effects of intravitreal Ranibizumab injection (IVR) and the efficacy of laser photocoagulation for the treatment of retinopathy of prematurity (ROP) are compared. The screening criteria for ROP were infants born with less than 32 weeks gestational period and/or weighed less than 1500 grams or unstable clinical course. After ethical approval from the Institutional Review Board, this retrospective study was conducted. The study considered 1315 infants and an observation was made that 36/42 (85.7%) eyes showed regression of ROP in the IVR group whereas 27/27 (100%) eyes that were treated with laser therapy showed regression of ROP (p=0.09). A considerable discrepancy in habituation of ROP in both groups with 12 eyes (28.6%) has been noted which is showing recurrence of ROP in the IVR group compared to 1 eye (3.7%) in the Laser group (P=0.01. In terms of anisometropia and refractive error, both groups made no notable difference. Squint was found remarkably higher in the laser group (29.6%) than in the IVR group (4.8%) (P=0.01). It was found that treating ROP eyes with laser treatment leads to greater improvement in infants than when treated by IVR. Moreover, a significant recurrence of ROP was discovered after IVR treatment in comparison with the laser treatment.

show abstract

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Cited by 2 publications

References 92 publications

Ranibizumab—The jury is still out

Ranibizumab—The jury is still out

Comparative Analysis of Intravitreal Ranibizumab versus Laser Therapy for Retinopathy of Prematurity

Contact Info

Product

Resources

About